The Ebola outbreak ravaging Democratic Republic of Congo (DRC) has now claimed over 2,000 lives, marking a grim milestone in the country’s fight against the deadly virus. Health officials warn the situation remains dire as the death toll continues to climb.

The DRC declared its 17th Ebola outbreak on May 15, months after the initial cases surfaced. Health experts have described this as the most severe outbreak in the nation’s history, with projections suggesting it could become the deadliest ever recorded globally.

According to the latest official figures, the outbreak has resulted in 2,011 fatalities out of 4,381 confirmed cases. The grim threshold of 1,000 deaths was crossed on July 22, underscoring the rapid escalation of the crisis.

This outbreak’s mortality rate stands at 45.9%, according to health authorities, highlighting the severe impact of the disease on affected communities.

Health Minister Samuel Roger Kamba cautioned that the outbreak has yet to reach its peak. Speaking at a press briefing on X, he noted, “We have not yet reached the peak of this crisis.”

Health officials outline timeline for control

Minister Kamba expressed cautious optimism about containing the outbreak within the next three months. He stated, “Within the next three months, we expect to have slowed the spread and begun to see a decline in new cases.”

Challenges hampering response efforts

The ongoing insecurity fueled by armed groups and deep-seated public distrust are severely hampering response efforts in the hardest-hit regions. Mohamed Yakub Janabi, Regional Director for Africa at the World Health Organization (WHO), revealed a troubling trend: “Only 30% of cases are being detected, while 70% of patients are dying at home.”

Janabi emphasized the uniqueness of this outbreak, stating, “This is why this Ebola outbreak is different from previous ones.”

Vaccine trials offer hope amid crisis

In a significant development, the WHO has recommended clinical trials for the Ervebo vaccine, the only approved vaccine for Ebola, to combat the current variant. The global stockpile of Ervebo, managed by Gavi, contains around 500,000 doses, with a portion permanently stationed in the DRC due to the country’s recurrent outbreaks.

Tedros Adhanom Ghebreyesus, Director-General of the WHO, shared positive updates on X, calling the vaccine trials “encouraging news.”

The WHO’s decision to fast-track the Ervebo trials to Phase 3 is supported by extensive safety data. Gavi confirmed that doses from the global stockpile will be made available to support these trials.

Additionally, Canada has approved Moderna to commence clinical trials for its vaccine targeting the Bundibugyo variant. Two other promising candidates are also in development: the rVSV Bundibugyo vaccine, developed by Hilleman Laboratories and deemed the most promising by WHO, and a vaccine from the University of Oxford, which administered its first dose to a volunteer in late July.

The United States has pledged over $242 million in additional funding to combat the Ebola outbreak in the DRC.

Ebola, transmitted through bodily fluids, causes severe hemorrhagic fever and has claimed over 15,000 lives in Africa over the past five decades.